When does ertugliflozin lose exclusivity in Europe?
Ertugliflozin (marketed as Steglatro by Merck, among others) is protected in Europe by a mix of patent rights and regulatory exclusivities. The exact date can differ by country and by which protection is being considered (basic patents vs. follow-on patents vs. patent term extensions and Supplementary Protection Certificates, where applicable). Without the specific country, product presentation, and the patent/SPC details you mean, a single definitive “loss of exclusivity in Europe” date cannot be stated from the information provided here.
How do “loss of exclusivity” dates usually differ across Europe?
In Europe, “loss of exclusivity” can mean different things depending on the legal layer involved:
- Patent/SPC expiry can allow generic or biosimilar manufacturers to make products, with launch often timed to when rights no longer block marketing.
- Regulatory exclusivities (if applicable) can delay market entry even if patents expire, depending on the product’s authorization pathway and legal status.
Because these protections can vary by jurisdiction and mechanism, the earliest possible entry date often comes from the earliest expiring controlling right, but the practical launch date may be later due to remaining protections.
Which patents matter most for ertugliflozin in Europe?
For drugs like ertugliflozin, generics typically watch:
- The expiry of the “main” compound patent family (if it exists in the form relevant to Europe).
- Follow-on patents (for specific formulations, dosing regimens, combinations, or crystall forms) that may extend market protection.
- Whether any Supplementary Protection Certificate (SPC) or patent term extension is in force, which can push expiry later than the underlying patent would suggest.
The specific controlling patent(s) can differ by country.
Can generics enter immediately after exclusivity expires?
In principle, generics can launch after the legal barriers are gone, but there can be timing differences due to:
- Remaining patent rights not yet expired in certain countries.
- Ongoing patent litigation or national disputes that can delay entry even after a theoretical expiry date.
- Product-specific factors (e.g., combination products, line extensions) that carry their own protection landscape.
How to find the exact “loss of exclusivity” date for your target country/product
To get a precise date for ertugliflozin in Europe, you generally need:
1) The country (e.g., UK vs. Germany vs. France; note that the UK can differ after Brexit).
2) The product strength and whether it is monotherapy or a combination.
3) The specific Steglatro marketing authorization number.
4) The controlling patent and whether an SPC is registered for that authorization.
If you tell me the European country (or countries) and whether you mean Steglatro (ertugliflozin) alone or a particular combination, I can narrow down what “loss of exclusivity” would mean in that setting and how to determine the controlling expiry date.
What to watch for: challenges, litigation, and “evergreening”
Even when the “headline” patent is due to expire, companies often file follow-on filings, and generics may challenge validity or infringement in court. This can create:
- Delay in launch even after an earlier expiry.
- Settlement-driven timing (where the generic may enter later than the earliest theoretical date).
- Country-to-country variation based on how litigation proceeds.
Commercial context: why the exact date is important
Drug market entry timing affects:
- Generic/competition planning and tender/contract negotiations.
- Forecasting payer budgets.
- Long-term brand strategy for Merck and partners in each EU member state.
---
Sources
No sources were provided with your question, so no citations can be included.